Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 184

1.

Peritoneal Protein Clearance Is a Function of Local Inflammation and Membrane Area Whereas Systemic Inflammation and Comorbidity Predict Survival of Incident Peritoneal Dialysis Patients.

Yu Z, Lambie M, Chess J, Williams A, Do JY, Topley N, Davies SJ.

Front Physiol. 2019 Feb 18;10:105. doi: 10.3389/fphys.2019.00105. eCollection 2019.

2.

Biocompatible Solutions and Long-Term Changes in Peritoneal Solute Transport.

Elphick EH, Teece L, Chess JA, Do JY, Kim YL, Lee HB, Davison SN, Topley N, Davies SJ, Lambie M.

Clin J Am Soc Nephrol. 2018 Oct 8;13(10):1526-1533. doi: 10.2215/CJN.02380218. Epub 2018 Aug 31. Erratum in: Clin J Am Soc Nephrol. 2019 Jun 7;14(6):909.

PMID:
30171050
3.

Targeting Toll-like receptors with soluble Toll-like receptor 2 prevents peritoneal dialysis solution-induced fibrosis.

Raby AC, González-Mateo GT, Williams A, Topley N, Fraser D, López-Cabrera M, Labéta MO.

Kidney Int. 2018 Aug;94(2):346-362. doi: 10.1016/j.kint.2018.03.014. Epub 2018 May 31.

PMID:
29861057
4.

The Authors Reply.

Zavvos V, Davies SJ, Topley N, Johnson TS.

Kidney Int. 2017 Nov;92(5):1290. doi: 10.1016/j.kint.2017.08.012. No abstract available.

PMID:
29055432
5.

Biomarker research to improve clinical outcomes of peritoneal dialysis: consensus of the European Training and Research in Peritoneal Dialysis (EuTRiPD) network.

Aufricht C, Beelen R, Eberl M, Fischbach M, Fraser D, Jörres A, Kratochwill K, LópezCabrera M, Rutherford P, Schmitt CP, Topley N, Witowski J.

Kidney Int. 2017 Oct;92(4):824-835. doi: 10.1016/j.kint.2017.02.037. Epub 2017 Aug 8. Review.

PMID:
28797473
6.

A prospective, proteomics study identified potential biomarkers of encapsulating peritoneal sclerosis in peritoneal effluent.

Zavvos V, Buxton AT, Evans C, Lambie M, Davies SJ, Topley N, Wilkie M, Summers A, Brenchley P, Goumenos DS, Johnson TS.

Kidney Int. 2017 Oct;92(4):988-1002. doi: 10.1016/j.kint.2017.03.030. Epub 2017 Jul 1.

7.

miR-21 Promotes Fibrogenesis in Peritoneal Dialysis.

Lopez-Anton M, Lambie M, Lopez-Cabrera M, Schmitt CP, Ruiz-Carpio V, Bartosova M, Schaefer B, Davies S, Stone T, Jenkins R, Taylor PR, Topley N, Bowen T, Fraser D.

Am J Pathol. 2017 Jul;187(7):1537-1550. doi: 10.1016/j.ajpath.2017.03.007. Epub 2017 May 9.

PMID:
28495592
8.

Machine-learning algorithms define pathogen-specific local immune fingerprints in peritoneal dialysis patients with bacterial infections.

Zhang J, Friberg IM, Kift-Morgan A, Parekh G, Morgan MP, Liuzzi AR, Lin CY, Donovan KL, Colmont CS, Morgan PH, Davis P, Weeks I, Fraser DJ, Topley N, Eberl M.

Kidney Int. 2017 Jul;92(1):179-191. doi: 10.1016/j.kint.2017.01.017. Epub 2017 Mar 17.

9.

Peritoneal macrophage heterogeneity is associated with different peritoneal dialysis outcomes.

Liao CT, Andrews R, Wallace LE, Khan MW, Kift-Morgan A, Topley N, Fraser DJ, Taylor PR.

Kidney Int. 2017 May;91(5):1088-1103. doi: 10.1016/j.kint.2016.10.030. Epub 2017 Jan 5.

10.

IL-6 Trans-Signaling Links Inflammation with Angiogenesis in the Peritoneal Membrane.

Catar R, Witowski J, Zhu N, Lücht C, Derrac Soria A, Uceda Fernandez J, Chen L, Jones SA, Fielding CA, Rudolf A, Topley N, Dragun D, Jörres A.

J Am Soc Nephrol. 2017 Apr;28(4):1188-1199. doi: 10.1681/ASN.2015101169. Epub 2016 Nov 11.

11.

Unconventional Human T Cells Accumulate at the Site of Infection in Response to Microbial Ligands and Induce Local Tissue Remodeling.

Liuzzi AR, Kift-Morgan A, Lopez-Anton M, Friberg IM, Zhang J, Brook AC, Roberts GW, Donovan KL, Colmont CS, Toleman MA, Bowen T, Johnson DW, Topley N, Moser B, Fraser DJ, Eberl M.

J Immunol. 2016 Sep 15;197(6):2195-207. doi: 10.4049/jimmunol.1600990. Epub 2016 Aug 15.

12.

Toll-Like Receptors 2 and 4 Are Potential Therapeutic Targets in Peritoneal Dialysis-Associated Fibrosis.

Raby AC, Colmont CS, Kift-Morgan A, Köhl J, Eberl M, Fraser D, Topley N, Labéta MO.

J Am Soc Nephrol. 2017 Feb;28(2):461-478. doi: 10.1681/ASN.2015080923. Epub 2016 Jul 18.

13.

IL-10 differentially controls the infiltration of inflammatory macrophages and antigen-presenting cells during inflammation.

Liao CT, Rosas M, Davies LC, Giles PJ, Tyrrell VJ, O'Donnell VB, Topley N, Humphreys IR, Fraser DJ, Jones SA, Taylor PR.

Eur J Immunol. 2016 Sep;46(9):2222-32. doi: 10.1002/eji.201646528. Epub 2016 Jul 28.

14.

Peritoneal Dialysate Glucose Load and Systemic Glucose Metabolism in Non-Diabetics: Results from the GLOBAL Fluid Cohort Study.

Lambie M, Chess J, Do JY, Noh H, Lee HB, Kim YL, Summers A, Williams PF, Davison S, Dorval M, Topley N, Davies SJ; Global Fluid Study Investigators.

PLoS One. 2016 Jun 1;11(6):e0155564. doi: 10.1371/journal.pone.0155564. eCollection 2016.

15.

Peritoneal inflammation precedes encapsulating peritoneal sclerosis: results from the GLOBAL Fluid Study.

Lambie MR, Chess J, Summers AM, Williams PF, Topley N, Davies SJ; GLOBAL Fluid Study Investigators.

Nephrol Dial Transplant. 2016 Mar;31(3):480-6. doi: 10.1093/ndt/gfv440. Epub 2016 Jan 26.

PMID:
26908833
16.

The use of exchange-free periods alternating with daily exchanges of icodextrin in the initial treatment of peritoneal dialysis-associated peritonitis: a safety study.

Yehia M, Muyoma G, Topley N, Collins JF.

Perit Dial Int. 2014 Nov-Dec;34(7):810-3. doi: 10.3747/pdi.2012.00347. No abstract available.

17.

Pathogen-Specific Immune Fingerprints during Acute Infection: The Diagnostic Potential of Human γδ T-Cells.

Eberl M, Friberg IM, Liuzzi AR, Morgan MP, Topley N.

Front Immunol. 2014 Nov 13;5:572. doi: 10.3389/fimmu.2014.00572. eCollection 2014. Review. No abstract available.

18.

Higher Dialysate Matrix Metalloproteinase-2 Levels Are Associated with Peritoneal Membrane Dysfunction.

Cho Y, Johnson DW, Vesey DA, Hawley CM, Pascoe EM, Clarke M, Topley N; balANZ Trial Investigators.

Perit Dial Int. 2016 Jan-Feb;36(1):16-25. doi: 10.3747/pdi.2013.00274. Epub 2014 Oct 7.

19.

Baseline serum interleukin-6 predicts cardiovascular events in incident peritoneal dialysis patients.

Cho Y, Johnson DW, Vesey DA, Hawley CM, Pascoe EM, Clarke M, Topley N; balANZ Trial Investigators.

Perit Dial Int. 2015 Jan-Feb;35(1):35-42. doi: 10.3747/pdi.2013.00272. Epub 2014 Apr 7.

20.

Utility of Urinary Biomarkers in Predicting Loss of Residual Renal Function: The balANZ Trial.

Cho Y, Johnson DW, Vesey DA, Hawley CM, Clarke M, Topley N; balANZ Trial Investigators.

Perit Dial Int. 2015 Mar-Apr;35(2):159-71. doi: 10.3747/pdi.2013.00170. Epub 2014 Apr 7.

21.

Interleukin-6 signaling drives fibrosis in unresolved inflammation.

Fielding CA, Jones GW, McLoughlin RM, McLeod L, Hammond VJ, Uceda J, Williams AS, Lambie M, Foster TL, Liao CT, Rice CM, Greenhill CJ, Colmont CS, Hams E, Coles B, Kift-Morgan A, Newton Z, Craig KJ, Williams JD, Williams GT, Davies SJ, Humphreys IR, O'Donnell VB, Taylor PR, Jenkins BJ, Topley N, Jones SA.

Immunity. 2014 Jan 16;40(1):40-50. doi: 10.1016/j.immuni.2013.10.022. Epub 2014 Jan 9.

22.

Dialysate interleukin-6 predicts increasing peritoneal solute transport rate in incident peritoneal dialysis patients.

Cho Y, Johnson DW, Vesey DA, Hawley CM, Pascoe EM, Clarke M, Topley N; balANZ Trial Investigators.

BMC Nephrol. 2014 Jan 10;15:8. doi: 10.1186/1471-2369-15-8.

23.

Pathogen-specific local immune fingerprints diagnose bacterial infection in peritoneal dialysis patients.

Lin CY, Roberts GW, Kift-Morgan A, Donovan KL, Topley N, Eberl M.

J Am Soc Nephrol. 2013 Dec;24(12):2002-9. doi: 10.1681/ASN.2013040332. Epub 2013 Oct 31.

24.

Independent effects of systemic and peritoneal inflammation on peritoneal dialysis survival.

Lambie M, Chess J, Donovan KL, Kim YL, Do JY, Lee HB, Noh H, Williams PF, Williams AJ, Davison S, Dorval M, Summers A, Williams JD, Bankart J, Davies SJ, Topley N; Global Fluid Study Investigators.

J Am Soc Nephrol. 2013 Dec;24(12):2071-80. doi: 10.1681/ASN.2013030314. Epub 2013 Sep 5.

25.

Targeting the TLR co-receptor CD14 with TLR2-derived peptides modulates immune responses to pathogens.

Raby AC, Holst B, Le Bouder E, Diaz C, Ferran E, Conraux L, Guillemot JC, Coles B, Kift-Morgan A, Colmont CS, Szakmany T, Ferrara P, Hall JE, Topley N, Labéta MO.

Sci Transl Med. 2013 May 15;5(185):185ra64. doi: 10.1126/scitranslmed.3005544.

26.

Suppression of pro-inflammatory T-cell responses by human mesothelial cells.

Lin CY, Kift-Morgan A, Moser B, Topley N, Eberl M.

Nephrol Dial Transplant. 2013 Jul;28(7):1743-50. doi: 10.1093/ndt/gfs612. Epub 2013 Jan 25.

PMID:
23355626
27.

Peritoneal fibrosis is mouse strain dependent.

Bodenham T, Topley N, Fraser D.

Nephrol Dial Transplant. 2013 Aug;28(8):1966-9. doi: 10.1093/ndt/gfs446. Epub 2012 Dec 18. No abstract available.

PMID:
23249621
28.

Peritoneal infection and inflammation.

Aufricht C, Neuhofer W, Topley N, Wörnle M.

Mediators Inflamm. 2012;2012:456985. doi: 10.1155/2012/456985. Epub 2012 Jun 7. No abstract available.

29.

Intraperitoneal IL-6 signaling in incident patients treated with icodextrin and glucose bicarbonate/lactate-based peritoneal dialysis solutions.

Opatrna S, Lysak D, Trefil L, Parker C, Topley N.

Perit Dial Int. 2012 Jan-Feb;32(1):37-44. doi: 10.3747/pdi.2010.00235.

30.

Proof-of-principle study to detect metabolic changes in peritoneal dialysis effluent in patients who develop encapsulating peritoneal sclerosis.

Dunn WB, Summers A, Brown M, Goodacre R, Lambie M, Johnson T, Wilkie M, Davies S, Topley N, Brenchley P.

Nephrol Dial Transplant. 2012 Jun;27(6):2502-10. doi: 10.1093/ndt/gfr662. Epub 2012 Jan 31.

PMID:
22294777
31.

Human peritoneal mesothelial cells respond to bacterial ligands through a specific subset of Toll-like receptors.

Colmont CS, Raby AC, Dioszeghy V, Lebouder E, Foster TL, Jones SA, Labéta MO, Fielding CA, Topley N.

Nephrol Dial Transplant. 2011 Dec;26(12):4079-90. doi: 10.1093/ndt/gfr217. Epub 2011 Jun 1.

32.

TLR activation enhances C5a-induced pro-inflammatory responses by negatively modulating the second C5a receptor, C5L2.

Raby AC, Holst B, Davies J, Colmont C, Laumonnier Y, Coles B, Shah S, Hall J, Topley N, Köhl J, Morgan BP, Labéta MO.

Eur J Immunol. 2011 Sep;41(9):2741-52. doi: 10.1002/eji.201041350. Epub 2011 Aug 4.

33.

Human neutrophil clearance of bacterial pathogens triggers anti-microbial γδ T cell responses in early infection.

Davey MS, Lin CY, Roberts GW, Heuston S, Brown AC, Chess JA, Toleman MA, Gahan CG, Hill C, Parish T, Williams JD, Davies SJ, Johnson DW, Topley N, Moser B, Eberl M.

PLoS Pathog. 2011 May;7(5):e1002040. doi: 10.1371/journal.ppat.1002040. Epub 2011 May 12.

34.

Esterified eicosanoids are acutely generated by 5-lipoxygenase in primary human neutrophils and in human and murine infection.

Clark SR, Guy CJ, Scurr MJ, Taylor PR, Kift-Morgan AP, Hammond VJ, Thomas CP, Coles B, Roberts GW, Eberl M, Jones SA, Topley N, Kotecha S, O'Donnell VB.

Blood. 2011 Feb 10;117(6):2033-43. doi: 10.1182/blood-2010-04-278887. Epub 2010 Dec 21.

35.

Switching on EMT in the peritoneal membrane: considering the evidence.

McLoughlin RM, Topley N.

Nephrol Dial Transplant. 2011 Jan;26(1):12-5. doi: 10.1093/ndt/gfq699. Epub 2010 Nov 10. No abstract available.

PMID:
21068140
36.

Naive and activated T cells display differential responsiveness to TL1A that affects Th17 generation, maintenance, and proliferation.

Jones GW, Stumhofer JS, Foster T, Twohig JP, Hertzog P, Topley N, Williams AS, Hunter CA, Jenkins BJ, Wang EC, Jones SA.

FASEB J. 2011 Jan;25(1):409-19. doi: 10.1096/fj.10-166843. Epub 2010 Sep 8.

37.

The pathophysiology of the peritoneal membrane.

Devuyst O, Margetts PJ, Topley N.

J Am Soc Nephrol. 2010 Jul;21(7):1077-85. doi: 10.1681/ASN.2009070694. Epub 2010 May 6. Review.

38.

Proteomics and peritoneal dialysis: early days but clear potential.

Brewis IA, Topley N.

Nephrol Dial Transplant. 2010 Jun;25(6):1749-53. doi: 10.1093/ndt/gfq145. Epub 2010 Mar 26. No abstract available.

39.

Interferon-gamma inhibits interleukin-1beta-induced matrix metalloproteinase production by synovial fibroblasts and protects articular cartilage in early arthritis.

Page CE, Smale S, Carty SM, Amos N, Lauder SN, Goodfellow RM, Richards PJ, Jones SA, Topley N, Williams AS.

Arthritis Res Ther. 2010;12(2):R49. doi: 10.1186/ar2960. Epub 2010 Mar 22.

40.

Salt intake induces epithelial-to-mesenchymal transition of the peritoneal membrane in rats.

Pletinck A, Consoli C, Van Landschoot M, Steppan S, Topley N, Passlick-Deetjen J, Vanholder R, Van Biesen W.

Nephrol Dial Transplant. 2010 May;25(5):1688-96. doi: 10.1093/ndt/gfq036. Epub 2010 Feb 11.

PMID:
20150166
41.

Loss of CD4+ T cell IL-6R expression during inflammation underlines a role for IL-6 trans signaling in the local maintenance of Th17 cells.

Jones GW, McLoughlin RM, Hammond VJ, Parker CR, Williams JD, Malhotra R, Scheller J, Williams AS, Rose-John S, Topley N, Jones SA.

J Immunol. 2010 Feb 15;184(4):2130-9. doi: 10.4049/jimmunol.0901528. Epub 2010 Jan 18.

42.

Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus.

Cash H, Relle M, Menke J, Brochhausen C, Jones SA, Topley N, Galle PR, Schwarting A.

J Rheumatol. 2010 Jan;37(1):60-70. doi: 10.3899/jrheum.090194. Epub 2009 Dec 1.

PMID:
19955044
43.

Altering peritoneal membrane function: removing the GAG?

Fraser DJ, Topley N.

Nephrol Dial Transplant. 2009 Nov;24(11):3271-3. doi: 10.1093/ndt/gfp440. No abstract available.

PMID:
19833665
44.

Functional effector memory T cells enrich the peritoneal cavity of patients treated with peritoneal dialysis.

Roberts GW, Baird D, Gallagher K, Jones RE, Pepper CJ, Williams JD, Topley N.

J Am Soc Nephrol. 2009 Sep;20(9):1895-900. doi: 10.1681/ASN.2008101127. Epub 2009 Aug 27.

45.

Nitric oxide synthase isoforms play distinct roles during acute peritonitis.

Ni J, McLoughlin RM, Brodovitch A, Moulin P, Brouckaert P, Casadei B, Feron O, Topley N, Balligand JL, Devuyst O.

Nephrol Dial Transplant. 2010 Jan;25(1):86-96. doi: 10.1093/ndt/gfp415. Epub 2009 Aug 25.

46.

Soluble TLR2 reduces inflammation without compromising bacterial clearance by disrupting TLR2 triggering.

Raby AC, Le Bouder E, Colmont C, Davies J, Richards P, Coles B, George CH, Jones SA, Brennan P, Topley N, Labéta MO.

J Immunol. 2009 Jul 1;183(1):506-17. doi: 10.4049/jimmunol.0802909.

47.

Phosphatidylethanolamine-esterified eicosanoids in the mouse: tissue localization and inflammation-dependent formation in Th-2 disease.

Morgan AH, Dioszeghy V, Maskrey BH, Thomas CP, Clark SR, Mathie SA, Lloyd CM, Kühn H, Topley N, Coles BC, Taylor PR, Jones SA, O'Donnell VB.

J Biol Chem. 2009 Aug 7;284(32):21185-91. doi: 10.1074/jbc.M109.021634. Epub 2009 Jun 15.

48.

A rapid crosstalk of human gammadelta T cells and monocytes drives the acute inflammation in bacterial infections.

Eberl M, Roberts GW, Meuter S, Williams JD, Topley N, Moser B.

PLoS Pathog. 2009 Feb;5(2):e1000308. doi: 10.1371/journal.ppat.1000308. Epub 2009 Feb 20.

49.

Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis.

Nowell MA, Williams AS, Carty SA, Scheller J, Hayes AJ, Jones GW, Richards PJ, Slinn S, Ernst M, Jenkins BJ, Topley N, Rose-John S, Jones SA.

J Immunol. 2009 Jan 1;182(1):613-22.

50.

How can genetic advances impact on experimental models of encapsulating peritoneal sclerosis?

Summers AM, Hoff CM, Topley N.

Perit Dial Int. 2008 Nov;28 Suppl 5:S16-20. Review. Erratum in: Perit Dial Int. 2009 Mar-Apr;29(2):131-2.

PMID:
19008534

Supplemental Content

Loading ...
Support Center